We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MIMETAS and Galapagos to Develop Human Disease Models On-a-Chip
News

MIMETAS and Galapagos to Develop Human Disease Models On-a-Chip

MIMETAS and Galapagos to Develop Human Disease Models On-a-Chip
News

MIMETAS and Galapagos to Develop Human Disease Models On-a-Chip

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MIMETAS and Galapagos to Develop Human Disease Models On-a-Chip"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MIMETAS and Galapagos have entered into a research collaboration on the development of organ-on-a-chip-based human disease models for new medicine development.

The companies will collaborate to develop miniaturized 3D cell culture models that mimic specific aspects of human diseases. These models will be applied to the identification and improvement of novel compounds.

Dr. Richard Janssen, Senior Director of Target Discovery at Galapagos, states: “The MIMETAS platform is the first to combine organ-on-a-chip technology with our high throughput screening of primary human cells. As we see it, OrganoPlates™ make 3D culture as straightforward as traditional cell culture.”

Dr. Jos Joore, MIMETAS’ CBO underscores this notion: “This agreement is a crucial step forward for MIMETAS and for the organ-on-a-chip field in general. Galapagos sets an example as one of the first drug discovery companies worldwide to implement innovative organ-on-a-chip technologies. This collaboration helps us to further validate our technology, by enabling development of unique novel compounds with unique human disease models.”

Financial and technological details of the agreement have not been disclosed.

Advertisement